AxoGen (AXGN) is a Great Momentum Stock: Should You Buy?
Axogen (AXGN) Stock Could Be 22% Overvalued On Cash Flow Expectations
Axogen, Inc. (AXGN) Discusses Prostate Nerve Reconstruction Market Development Transcript
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen: Taking The Friction Out Of Nerve Repair
Canaccord Genuity Maintains Buy on Axogen, Raises Price Target to $60
Leerink Partners Maintains Outperform on Axogen, Raises Price Target to $56
Is AxoGen (AXGN) Outperforming Other Medical Stocks This Year?
Barclays Maintains Overweight on Axogen, Raises Price Target to $60
Truist Securities Maintains Buy on Axogen, Raises Price Target to $60
Wells Fargo Maintains Overweight on Axogen, Raises Price Target to $56
HC Wainwright & Co. Maintains Buy on Axogen, Raises Price Target to $56
Does Axogen (AXGN) Have More Upside Or Is It Fully Priced?
AxoGen Q3 Earnings Call Highlights
AxoGen: Q3 Earnings Snapshot
Axogen (AXGN) Q3 2026 Earnings Call Transcript
Axogen, Inc. 2026 Q3 - Results - Earnings Call Presentation
Axogen (NASDAQ:AXGN) Stock Jumps on Q3 Earnings Beat and Strong 2026 Revenue Guidance
Axogen, Inc. (AXGN) Q3 2026 Earnings Call Transcript
AxoGen (AXGN) Beats Q3 Earnings and Revenue Estimates
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.